Authors
Latest:
Peter Humphrey, MD, PhD, Discusses Current Role of Pathology in RCCAt the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.
Latest:
CAR T in R/R MM: Key Takeaways and PearlsPanelists discuss how successful implementation of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM) depends on early referral, coordinated care between academic and community centers, standardized protocols for patient management, and careful consideration of product selection and timing based on individual patient factors.
Latest:
Taste Change Data May Inform Radiotherapy Strategy in Head and Neck CancerFindings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Latest:
HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in CareClosing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.
Latest:
Closing Thoughts on Bispecific Antibodies and the Future of R/R MM TreatmentThe panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.
Latest:
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS DiseaseShared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
Latest:
Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in CancerFareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
MRD and Decision-Making in Early-Stage Colorectal CancerThis article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.
Latest:
Expert Commentary on the Product Profile of AsciminibIn an interview with ONCOLOGY®, Elizabeth Travers, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of asciminib as therapy for patients with chronic myeloid leukemia.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Closing Thoughts: Key Messages for Clinicians and Patients in the Treatment of HER2+ Breast CancerPanelists discuss advice for nurses collaborating with oncologists in treating patients with HER2+ breast cancer, as well as closing messages for patients receiving treatment and clinicians involved in the care of those with advanced HER2+ breast cancer.
Latest:
Candice Roth, MSN, RN, CENP, Describes the Evolution of Electronic Treatment Pathways at Levine Cancer InstituteCandice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
